Cidofovir

2月26日，优宁维跌0.45%，成交额2801.67万元，换手率1.48%，总市值28.90亿元。异动分析基因测序+医药电商+细胞免疫治疗+重组蛋白+猴痘概念1、根据公司官网，公司有单细胞DNA测序，单细胞RNA测序产品。2、2025年12月26日互动易，公司目前形成了线上+线下双渠道销售模式，线上渠道方面，主要通过自有商城、微信、抖音等平台以及第三方专业服务网站展示、销售公司产品，提升公司产品曝光度；此外针对海外市场，目前主要通过海外电商平台、参加海外展会等方式进行市场拓展。3、公司在细胞治疗领域的产品主要为抗体及抗体相关试剂、其他生物科学试剂、仪器及耗材和综合技术服务。4、公司作为生命科学一站式服务商，面向高等院校、科研院所、医院和生物医药企业等，提供以抗体为核心的生命科学试剂及相关仪器、耗材和综合技术服务。公司抗体相关试剂产品包括基于抗体应用技术开发的检测试剂盒、重组蛋白/多肽、辅助试剂，重组蛋白主要作为添加剂用于细胞培养，或作为标准品用于定量检测试剂盒标准曲线的绘制等。公司产品和服务覆盖药物研发（以生物药为主，如抗体药、重组蛋白药、细胞治疗等）的药物发现、临床前研究、临床研究等各环节。5、公司商城中在售的特考韦瑞、西多福韦，均用于科研领域，上述产品为公司爱必信旗下的ODM产品，非自产产品。目前上述产品对公司收入贡献很小。（注：国泰君安研报表示：根据美国CDC，目前尚无针对猴痘的特效疗法，但可结合天花疫苗，以及西多福韦、Brincidofovir、特考韦瑞、痘苗免疫球蛋白等药物，将猴痘疫情控制住。）(免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断)资金分析今日主力净流入41.68万，占比0.01%，行业排名15/55，该股当前无连续增减仓现象，主力趋势不明显；所属行业主力净流入-4.76亿，当前无连续增减仓现象，主力趋势不明显。区间今日近3日近5日近10日近20日主力净流入41.68万-322.10万-585.54万-995.76万-2462.08万主力持仓主力没有控盘，筹码分布非常分散，主力成交额668.90万，占总成交额的3.41%。技术面：筹码平均交易成本为32.24元该股筹码平均交易成本为32.24元，近期该股有吸筹现象，但吸筹力度不强；目前股价在压力位33.96和支撑位32.36之间，可以做区间波段。公司简介资料显示，上海优宁维生物科技股份有限公司位于上海市浦东新区古丹路15弄16号楼，成立日期2004年10月22日，上市日期2021年12月28日，公司主营业务涉及面向高等院校、科研院所、医院和生物医药企业等,提供以抗体为核心的生命科学试剂及相关仪器、耗材和综合技术服务。主营业务收入构成为：生命科学试剂77.94%，生命科学仪器及耗材16.11%，综合技术服务5.95%。优宁维所属申万行业为：医药生物-生物制品-其他生物制品。所属概念板块包括：微盘股、小盘价值、小盘、增持回购、科学仪器等。截至9月30日，优宁维股东户数9893.00，较上期减少13.19%；人均流通股5753股，较上期增加15.19%。2025年1月-9月，优宁维实现营业收入7.76亿元，同比减少6.24%；归母净利润-1507.96万元，同比减少207.11%。分红方面，优宁维A股上市后累计派现1.82亿元。近三年，累计派现1.38亿元。机构持仓方面，截止2025年9月30日，优宁维十大流通股东中，诺安多策略混合A（320016）位居第八大流通股东，持股49.91万股，为新进股东。声明：市场有风险，投资需谨慎。本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本文出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系biz@staff.sina.com.cn。

In a subgroup analysis of people living with HIV enrolled in PRIOH-1, pritelivir demonstrated superior lesion healing, achieving 61% complete lesion healing compared with 20% receiving investigator’s choice therapy (ICT) with an adjusted treatment difference of 37% (p = 0.027) in people living with HIV with refractory HSV infections The results were presented as a late-breaking oral presentation at the Conference on Retroviruses and Opportunistic Infections (CROI), which focuses on key clinical and scientific innovations in human retrovirus-associated diseases like HIV Wuppertal, Germany, February 25, 2026 - Aicuris Anti-infective Cures AG (“Aicuris”) today announced superior efficacy results from a subgroup analysis of its pivotal Phase 3 trial (PRIOH-1) evaluating pritelivir vs. investigator’s choice in people living with HIV with refractory herpes simplex virus (HSV) infection. The results were presented as a late-breaking oral presentation at the Conference on Retroviruses and Opportunistic Infections (CROI) on February 25, 2026, in Denver, USA. People living with HIV face a higher risk of severe, refractory HSV infections due to weakened immunity. HSV-2 also increases HIV acquisition risk, and co-infection can cause aggressive, prolonged, painful lesions and may accelerate HIV progression. Repeated antiviral use for treatment of HSV recurrence increases the risk of resistance, underscoring the urgent need for more effective HSV therapies for this vulnerable population. “Patients living with HIV who develop refractory HSV infections with or without acyclovir resistance often present with prolonged, atypical, and clinically challenging disease courses,” said Professor Jean-Michel Molina, University of Paris Cité, Department of Infectious Diseases, Saint-Louis and Lariboisière Hospitals APHP, Paris France , a principal investigator in the PRIOH-1 study who made the presentation at CROI. “The subgroup analysis from this Phase 3 trial provides important evidence that pritelivir can achieve meaningful lesion healing in this population, using an oral treatment option. These data add an important piece to our understanding of how refractory HSV can be managed in people living with HIV.” In the subgroup, people living with HIV represented 37.6% (38/101) of all immunocompromised patients enrolled in the PRIOH-1 Phase 3 trial and had a mean CD4 cell count of 334.8 cells/mm³. Among these patients, 81.6% (31/38) had refractory HSV (no clinical improvement in HSV lesions after ≥ 7 days of treatment), and 18.4% (7/38) had laboratory-confirmed acyclovir resistance. 40% of the study cohort had another underlying immunosuppressive condition. Similar to other subgroups, pritelivir achieved superior lesion healing of 61% (14/23) within up to 28 days of treatment, compared with 20% (3/15) for ICT, with an adjusted treatment difference of 37%, p = 0.027 [95%CI 7.6, 66.8] (post-hoc analysis). The majority (96%) of people living with HIV completed pritelivir treatment compared with 60% in the investigator’s choice treatment group. “People living with HIV often experience more complex clinical manifestations of HSV, which can make infections particularly difficult to treat,” said Cynthia Wat, CMO of Aicuris . “As an antiviral with a novel mechanism of action, pritelivir has shown efficacy in the treatment of refractory HSV infections with or without resistance (R±R) and may offer an important option for people living with HIV facing severe, refractory HSV disease.” Aicuris announced positive efficacy and favorable safety results for pritelivir at the 2026 Tandem Meetings earlier this month. The global, controlled, open-label comparative trial (PRIOH-1, NCT03073967 / Eudra-CT 2023-510088-37-00 ) included 101 randomized patients and 56 non-randomized patients with R±R HSV infection, including patients living with HIV, hematopoietic stem-cell and solid organ transplant patients, and patients with malignancies, autoimmune or inflammatory disorders. Patients were treated with either oral pritelivir or ICT (IV foscarnet, IV/topical cidofovir, or topical imiquimod). Pritelivir demonstrated a favorable safety and tolerability profile. It was associated with fewer renal, electrolyte events and drug-related TEAE discontinuations (2.0%) compared with ICT (20.0%). The most common TEAEs that occurred while receiving pritelivir were headache (13.7%), diarrhea (11.8%), nausea (7.8%), decreased appetite (7.8%), vomiting (5.9%) and dizziness (5.9%). About Herpes Simplex Virus Herpes Simplex Virus (HSV) includes two types, HSV-1 and HSV-2, both of which cause lifelong infections. HSV-1 most commonly causes labial herpes, typically presenting as cold sores, while HSV-2 is the primary cause of genital herpes. HSV infections are characterized by recurrent, painful lesions and sores and, in severe cases, can lead to complications such as encephalitis, meningitis, disseminated disease, keratitis and neonatal herpes. HSV infections represent a substantial global public health burden. According to the World Health Organization, an estimated 3.8 billion people under the age of 50, or 64% of the global population, were infected with HSV-1 in 2020. 520 million people aged 15 to 49 were living with HSV-2. The disease burden is particularly high in immunocompromised patients, who are at increased risk of more severe, more frequent and treatment-refractory HSV infections. About Pritelivir Pritelivir, a novel helicase-primase inhibitor developed by Aicuris, targets both HSV-1 and HSV-2. These viruses are responsible for genital, oral, or disseminated infections with increasing severity and limited treatment options, particularly in immunocompromised patients where being treatment refractory or resistant to existing antivirals is a significant clinical challenge. Unlike traditional antivirals, pritelivir blocks viral DNA synthesis by inhibiting the helicase-primase complex, a mechanism distinct from marketed nucleoside analogues. Because of this distinct mode of action, pritelivir is active against strains resistant to nucleoside analog and foscarnet based therapies. 1 Earlier clinical trials in immunocompetent and immunocompromised individuals showed a favorable safety pro early signals of clinical efficacy compared to standard of care treatments like valacyclovir and foscarnet. Based on these results, pritelivir was granted FDA Breakthrough Therapy designation. In October 2025, Aicuris announced that pritelivir met its primary endpoint in the pivotal Phase 3 trial. About Aicuris Aicuris is meeting the needs of the growing population of immunocompromised people who require precise therapies to effectively treat infection. Our flagship product, PREVYMIS ® , marketed by our partner MSD, prevents CMV in a defined group of transplant recipients. Our pivotal Phase 3 candidate, pritelivir, aims to address refractory HSV infections in a broad population of patients with weakened immune systems. For immunocompromised people, an otherwise manageable infection can mean life or death. Aicuris, with its expertise and growing pipeline, is committed to providing therapeutic solutions for them now and in the future. Contact: Aicuris Anti-infective Cures AG Email: info@aicuris.com Trophic Communications Dr. Stephanie May and Anja Heuer Phone: +49 171 1855 682 Email: aicuris@trophic.eu 1 Sallée, L. and Boutolleau, D. (2024), Management of Refractory/Resistant Herpes Simplex Virus Infections in Haematopoietic Stem Cell Transplantation Recipients: A Literature Review. Rev Med Virol, 34: e2574. Attachment CROI PR